Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial

Yuanming Shen, Nalan Tu, Beihua Kong, Bairong Xia, Yonghui Zou, Rutie Yin, Qingshui Li, Ying Yue, Shan Kang, Ke Wang, Liping He, Shixuan Wang, Yuanguang Meng, Pengpeng Qu, Xianghua Huang, Ruixia Guo, Ping Yan, Mei Pan, Wenjun Cheng, Ge Lou, Zehua Wang

Therapeutic Advances in Medical Oncology

Published online on February 16, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:The current standard-of-care chemotherapy for treatment-naïve epithelial ovarian cancer is paclitaxel plus carboplatin.Objectives:To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin versus paclitaxel ...